25 Jul 2021

CDMOs – Growth Through Complexities and Opportunities

PDF 9.9 MB

It is a fascinating, exciting and challenging time to be a contract manufacturing and development organisation (CDMO). Increasing drug complexity, growing interest in cell and gene therapies and the COVID-19 pandemic are all having a dramatic impact on the CDMO space. This report examines how CDMOs are reshaping their outsourcing offering to better meet the changing demands of their pharmaceutical customers, and which strategies are being employed to take full advantage of what appears to be an unprecedented growth opportunity for both sides of the partnership.

Content provided by our supplier

Adare Pharma Solutions

  • US
  • 2015
    On CPHI since
  • 2
  • 500 - 999
Company types
Contract Service
Packaging supplier/manufacturer
Primary activities
Contract Manufacturer
Out-licensing specialist
Packaging & drug delivery

Other Content from Adare Pharma Solutions (25)